cdmo.directory
← Compare landing

SEQENS vs Sterling Pharma Solutions

Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.

CategorySEQENSSterling Pharma Solutions
SummaryGlobal CDMO and specialty ingredients manufacturer with 16 production sites and 9 R&D centres offering custom development and GMP manufacturing of pharmaceutical APIs, intermediates, and specialty chemicals from preclinical to commercial scale.Small molecule CDMO offering comprehensive API development and manufacturing from discovery through commercial cGMP production, with specialized expertise in complex and hazardous chemistries and ADC bioconjugation.
Services
  • Small Molecule Development & Manufacturing
  • API Synthesis & Manufacturing
  • Flow Chemistry & Continuous Manufacturing
  • Process Development
  • Technology Transfer
  • CMC Analytical Development
  • Quality Control Testing
  • CMC Regulatory Submission Support
  • Small Molecule Development & Manufacturing
  • API Synthesis & Manufacturing
  • HPAPI Manufacturing (High-Potency)
  • Controlled Substance Manufacturing
  • Flow Chemistry & Continuous Manufacturing
  • Solid-State Chemistry & Polymorph Screening
  • ADC (Antibody-Drug Conjugate) Manufacturing
  • ADC Payload & Linker Synthesis
  • Bioconjugation Services
  • Peptide Manufacturing
  • Process Development
  • Technology Transfer
  • CMC Analytical Development
  • Quality Control Testing
  • CMC Regulatory Submission Support
Modalities
  • Small Molecule
  • Small Molecule
  • Antibody-Drug Conjugate (ADC)
  • Peptide
Development capabilities
  • Analytical method development
  • Analytical method development
  • Solid-state characterization
Manufacturing capabilities
  • Drug Substance (DS)
  • Max chemical: Commercial (>100 kg / tonne)
  • Flow Chemistry
  • Drug Substance (DS)
  • Max chemical: Commercial (>100 kg / tonne)
  • HPAPI
  • DEA licensed
  • Flow Chemistry
Locations
  • Headquarters, France
  • France, France, France
  • Production & R&D, Europe, France
  • United Kingdom, United Kingdom, United Kingdom
  • Production & R&D, Europe, United Kingdom
  • Production, Israel
  • Production & R&D Sites, Europe and Israel
  • Custom Chemistry Plants, France and UK
  • Headquarters / Global Operations
  • Manufacturing & R&D, Europe, France
  • Manufacturing & R&D, Europe, United Kingdom
  • Manufacturing, Israel
  • Israel, Israel, Israel
  • Europe & Israel Operations, Europe, Israel
  • Production & R&D, Europe and Israel
  • Cork, Cork, Munster, Ireland
  • Cramlington, Cramlington, Northumberland, United Kingdom
  • Deeside, Deeside, Wales, United Kingdom
  • Newcastle Biosphere, Newcastle, Tyne and Wear, United Kingdom
  • North Carolina, North Carolina, North Carolina, United States
  • Wisconsin, Wisconsin, Wisconsin, United States
  • North Carolina, North Carolina, North Carolina, US
  • Wisconsin, Wisconsin, Wisconsin, US
  • Newcastle Biosphere, Newcastle, England, UK
  • North Carolina, North Carolina, US
  • Wisconsin, Wisconsin, US
  • Cramlington, Cramlington, England, UK
  • North Carolina, North Carolina, North Carolina, USA
  • Wisconsin, Wisconsin, Wisconsin, USA
Certifications
  • FDA · Identifier: GMP inspected
  • EcoVadis · Identifier: Platinum certified
  • EcoVadis · Identifier: Gold & Platinum certifications
  • FDA · Identifier: FDA-inspected plants
  • EcoVadis · Identifier: Platinum certification
  • FDA · Identifier: GMP, FDA inspected
  • FDA · Identifier: GMP-inspected
  • EcoVadis · Identifier: Platinum
  • FDA · Identifier: GMP inspected plants
  • FDA · Identifier: cGMP inspection
  • HPRA · Identifier: cGMP inspection (mutually recognised by FDA)
  • PMDA · Identifier: Project specific inspection
  • ANVISA · Identifier: Project specific inspection
  • MHRA · Identifier: cGMP inspection
  • DEA · Identifier: Schedule I-V controlled substances approval
  • ISO · Identifier: ISO/IEC 27001:2022, ISO/IEC 9001:2015, ISO 45001:2018, ISO 14001:2015
  • FDA · Identifier: cGMP inspection January 2017
  • PMDA · Identifier: project specific inspection June 2022
  • HPRA · Identifier: cGMP inspection March 2022
  • ANVISA · Identifier: project specific inspection 2021
  • MHRA · Identifier: cGMP inspection June 2021
  • FDA · Identifier: cGMP inspection May 2018
  • MHRA · Identifier: cGMP inspection April 2023
  • FDA · Identifier: Registered as bulk API manufacturer
  • DEA · Identifier: Approved to import, store, manufacture and export Schedule I-V controlled substances
  • FDA · Identifier: cGMP inspection March 2024
  • cGMP · Identifier: cGMP accreditation

Find similar companies

SEQENS alternatives · Sterling Pharma Solutions alternatives

Markdown mirror: /compare/seqens/sterlingpharmasolutions.md